- Home
- PERF vs VNDA Comparison
PERF vs VNDA Comparison
Compare PERF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- VNDA
- Stock Information
- Founded
- PERF 2015
- VNDA 2002
- Country
- PERF Taiwan
- VNDA United States
- Employees
- PERF N/A
- VNDA N/A
- Industry
- PERF Computer Software: Prepackaged Software
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PERF Technology
- VNDA Health Care
- Exchange
- PERF Nasdaq
- VNDA Nasdaq
- Market Cap
- PERF 230.2M
- VNDA 282.8M
- IPO Year
- PERF N/A
- VNDA 2006
- Fundamental
- Price
- PERF $1.79
- VNDA $4.92
- Analyst Decision
- PERF Buy
- VNDA Strong Buy
- Analyst Count
- PERF 1
- VNDA 2
- Target Price
- PERF $5.00
- VNDA $16.50
- AVG Volume (30 Days)
- PERF 192.8K
- VNDA 776.8K
- Earning Date
- PERF 04-23-2025
- VNDA 02-13-2025
- Dividend Yield
- PERF N/A
- VNDA N/A
- EPS Growth
- PERF 8.96
- VNDA N/A
- EPS
- PERF 0.05
- VNDA N/A
- Revenue
- PERF $60,202,000.00
- VNDA $198,772,000.00
- Revenue This Year
- PERF $17.47
- VNDA $14.36
- Revenue Next Year
- PERF $13.15
- VNDA $44.53
- P/E Ratio
- PERF $36.00
- VNDA N/A
- Revenue Growth
- PERF 12.52
- VNDA 3.18
- 52 Week Low
- PERF $1.70
- VNDA $3.71
- 52 Week High
- PERF $3.44
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- PERF 40.11
- VNDA 56.51
- Support Level
- PERF $1.75
- VNDA $4.65
- Resistance Level
- PERF $1.97
- VNDA $5.10
- Average True Range (ATR)
- PERF 0.17
- VNDA 0.24
- MACD
- PERF -0.00
- VNDA 0.03
- Stochastic Oscillator
- PERF 8.94
- VNDA 69.66
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.